Shanghai - Delayed Quote CNY

Autobio Diagnostics Co., Ltd. (603658.SS)

56.19 -0.04 (-0.07%)
As of 11:29 AM GMT+8. Market Open.
Loading Chart for 603658.SS
DELL
  • Previous Close 56.23
  • Open 55.93
  • Bid 56.16 x --
  • Ask 56.19 x --
  • Day's Range 55.65 - 56.75
  • 52 Week Range 41.01 - 66.36
  • Volume 3,268,502
  • Avg. Volume 4,092,935
  • Market Cap (intraday) 32.943B
  • Beta (5Y Monthly) -0.10
  • PE Ratio (TTM) 25.08
  • EPS (TTM) 2.24
  • Earnings Date --
  • Forward Dividend & Yield 0.80 (1.42%)
  • Ex-Dividend Date Jun 12, 2023
  • 1y Target Est 66.05

Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products. It develops immunoassay, biochemistry, and microbiology products, as well as reagents; and instruments, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A1860 that provides user experience for small and medium size labs; an automated chemiluminescence immunoassay analyzer; AutoLumo A2000 Plus, an automatic chemiluminescence immunoassay analyzer; AutoLumo A1000, an automated chemiluminescence immunoassay analyzer; and LUmo microplate luminometers, PHOmo microplate readers, and iWO and iWO-960 microplate washers. Its microbiology products BC60, an automatic blood culture instrument; MALDI-TOF MS system for the identification of pathogenic bacteria; AutoMic-I60 for microbial identification and antibiotic susceptibility testing; BC120, an automated blood culture system; and AutoMimo 1200, an instrument for improving pipetting efficiency and optimize workflow in the lab. The company also offers blood culture bottles, AST cards, mycoplasma TIES, and AUTOF MS reagents; AutoMolec 1600, an integrated and automated molecular diagnostics analyzer; and AutoMolec 3000, an in vitro molecular detection instrument. In addition, it engages in biological research and development; and the provision of technical and support services. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is headquartered in Zhengzhou, China. Autobio Diagnostics Co., Ltd. operates as a subsidiary of Zhengzhou Autobio Co., Ltd.

www.autobio.com.cn

5,539

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 603658.SS

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

603658.SS
1.44%
SSE Composite Index
3.43%

1-Year Return

603658.SS
1.64%
SSE Composite Index
5.76%

3-Year Return

603658.SS
36.15%
SSE Composite Index
11.43%

5-Year Return

603658.SS
25.79%
SSE Composite Index
1.50%

Compare To: 603658.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603658.SS

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    32.97B

  • Enterprise Value

    32.14B

  • Trailing P/E

    25.10

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.26

  • Price/Book (mrq)

    3.75

  • Enterprise Value/Revenue

    7.15

  • Enterprise Value/EBITDA

    21.72

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    28.90%

  • Return on Assets (ttm)

    7.25%

  • Return on Equity (ttm)

    15.35%

  • Revenue (ttm)

    4.5B

  • Net Income Avi to Common (ttm)

    1.3B

  • Diluted EPS (ttm)

    2.24

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.58B

  • Total Debt/Equity (mrq)

    8.53%

  • Levered Free Cash Flow (ttm)

    666.31M

Research Analysis: 603658.SS

Analyst Price Targets

62.54
66.05 Average
56.19 Current
73.00 High
 

Earnings

Consensus EPS
 

Company Insights: 603658.SS

People Also Watch